Neurocrine Biosciences, Inc.

Neurocrine Biosciences, Inc. is a biopharmaceutical company dedicated to discovering, developing, and commercializing innovative treatments for a range of challenging neurological, psychiatric, endocrine, and immunological disorders. The company has established a strong market presence with its approved therapies, including INGREZZA, a leading treatment for tardive dyskinesia and chorea associated with Huntington's disease, and Orilissa and Oriahnn, which address significant unmet needs in women's health for endometriosis and uterine fibroids, respectively. Neurocrine Biosciences also offers CRENESSITY for congenital adrenal hyperplasia, alongside other specialized products like ALKINDI and Efmody. Its robust pipeline reflects a strategic focus on areas with substantial patient populations and limited therapeutic options, featuring numerous product candidates in various stages of clinical development targeting conditions such as movement disorders, major depressive disorder, schizophrenia, Alzheimer's disease, epilepsy, and obesity. The company actively pursues growth through both internal research and development and strategic collaborations with leading pharmaceutical partners, underscoring its commitment to advancing scientific innovation and delivering life-changing medicines to patients worldwide.